Novel investigational therapeutics for generalized anxiety disorder (GAD)

Keyphrases

• Generalized Anxiety Disorder 100%
• Investigational Drugs 100%
• Depressive 66%
• Phase I Study 66%
• Signal Detection 66%
• Responsivity 33%
• Placebo 33%
• Comorbidity 33%
• Trial Design 33%
• PubMed 33%
• Treatment Options 33%
• New Drugs 33%
• Expert Opinion 33%
• Clinical Development 33%
• Dopamine 33%
• Serotonin 33%
• Neuropeptides 33%
• Area Cover 33%
• Neuroplasticity 33%
• Psychiatric Conditions 33%
• Placebo Response Rate 33%
• Sequential Parallel Comparison Design 33%
• Anxiety Comorbidity 33%
• Glutamatergic Activity 33%
• Monoaminergic System 33%
• Corticotropin-releasing Factor 33%
• GABAergic Activity 33%
• Pathophysiological Models 33%
• Glutamate 33%
• Cost to Society 33%
• Clinical Phase 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Generalized Anxiety Disorder 100%
• Placebo 66%
• Comorbidity 66%
• Serotonin 33%
• Noradrenalin 33%
• Neuropeptide 33%
• Glutamic Acid 33%
• Corticotropin Releasing Factor 33%
• Investigational Drug 33%
• Dopamine 33%
• Side Effect 33%